COX II INHIBITOR CELECOXIB IN HEMOPHILIC ARTHROPATHY IN HEMOPHILIA A AND B PTP CHILDREN

Abstract

Hemophilic arthropathy is the most debilitating complication of hemophilia resulting in chronic joint pain and diminished range of motion that requires multidisciplinary approach of management. Non selective non steroidal anti-inflammatory drugs (ns-NSAID) are analgesic, anti-inflammatory drugs used for different types of arthropathies with limited usage in hemophilia for its high risk of GIT toxicities. Selective COX-2 inhibitor celecoxib (Celebrex ®) is an analgesic, anti-inflammatory and anti-angiogenic agent with low GIT toxicity. This cross sectional study was conducted on 50 patients with hemophilia A and B followed at pediatric hematology clinic, Ain Shams University. Patients were randomly divided into 2 equal groups. Group A: patients who received factor replacement therapy and oral celecoxib on 3 mg/kg/day for 30 days and group B patients who did not receive Celebrex with their factor replacement therapy.